About caplacizum ab
Von Willebrand factor inhibitor
Used for
- Treatment of acquired thrombotic thrombocytopenic purpura (aTTP), with plasma exchange and immunosuppressive therapy.
Usual adult dose
Initial 11 mg intravenously before plasma exchange, then 11 mg under the skin after exchange; continue daily during exchange and for 30 days afterward. Longer treatment may be needed.
Common side effects
- Nosebleeds
- Headache
- Bleeding gums
- Bruising
Important warnings
- Increases bleeding risk; serious or fatal bleeding can occur.
- Use caution with anticoagulants, antiplatelet medicines, or bleeding disorders.
- Stop and seek urgent care for severe or uncontrolled bleeding.
- Treatment should be supervised by a clinician experienced in aTTP.
Pregnancy
Limited human information; use only when clearly needed, as potential fetal risks are uncertain.
Breastfeeding
It is unknown whether caplacizumab passes into breast milk; consider treatment benefits and potential risks.
Interactions
- Anticoagulants and antiplatelet medicines may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.